MacroGenics (MGNX) Projected to Post Earnings on Thursday

MacroGenics (NASDAQ:MGNX - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect MacroGenics to post earnings of ($0.61) per share and revenue of $9.59 million for the quarter.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $49.40 million for the quarter, compared to analysts' expectations of $34.17 million. MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Stock Performance

Shares of NASDAQ:MGNX traded down $0.17 during midday trading on Tuesday, reaching $1.47. 692,507 shares of the company's stock traded hands, compared to its average volume of 1,133,461. MacroGenics has a one year low of $0.99 and a one year high of $16.37. The company has a market cap of $92.74 million, a price-to-earnings ratio of -0.93 and a beta of 2.20. The stock has a 50 day moving average of $1.68 and a 200 day moving average of $2.72.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MGNX shares. StockNews.com downgraded shares of MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reduced their price objective on MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $7.38.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.